4th Internatinal TPCF Preclinical Imaging Symposium
Due to the huge costs and time spent for development of new drugs (around almost $ 1 billion (USD) and 12 Years), investing on the preclinical phase of drug development could be regarded as a great investment for de-risking the clinical phases. Preclinical studies are performed to obtain basic info...
Enregistré dans:
Auteur principal: | 4th Internatinal TPCF Preclinical Imaging |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Tehran University of Medical Sciences
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a53c7a8a6c154ea9856525d97e14f071 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Utilidad clínica de la fusión SPECT/CT con marcadores externos en patología oncológica
par: Aqueveque A,Carolina, et autres
Publié: (2007) -
Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
par: Massardo,Teresa, et autres
Publié: (2007) -
Arteritis de células gigantes: compromiso extenso de la aorta y grandes ramas demostrado por tomografía por emisión de positrones. Caso clínico
par: Grünholz,Daniela, et autres
Publié: (2016) -
Tunable and noncytotoxic PET/SPECT-MRI multimodality imaging probes using colloidally stable ligand-free superparamagnetic iron oxide nanoparticles
par: Pham THN, et autres
Publié: (2017) -
In-111 octreotide SPECT/CT in the early diagnosis of pulmonary sarcoidosis: A case report
par: Roberto G. Carbone, MD, et autres
Publié: (2022)